From: Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients
 | Univariate analyses | Multivariate analysis | ||||||
---|---|---|---|---|---|---|---|---|
Marker expression | Patients (n) | Patients (%) | Median survival (months) | 5-Year survival (%) | P | HR | 95% CI | P |
FGF2 | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 75 | 69 | NR | 68 | 0.048 | 1.000 | Â | Â |
High | 30 | 28 | 54 | 50 | Â | 2.203 | 1.108-4.379 | 0.024 |
Missing | 3 | 3 | Â | Â | Â | Â | Â | Â |
FGFR-1 | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 78 | 72 | NR | 61 | 0.830 | Â | Â | Â |
High | 28 | 26 | NR | 62 | Â | Â | Â | Â |
Missing | 2 | 2 | Â | Â | Â | Â | Â | Â |
FGF2 & PDGF-B | Â | Â | Â | Â | Â | Â | Â | 0.007* |
Low | 27 | 25 | NR | 81 | 0.011 | 1.000 | Â | Â |
Intermediate | 52 | 48 | NR | 59 | Â | 3.569 | 1.311-9.715 | 0.013 |
High | 25 | 23 | 45 | 48 | Â | 5.971 | 1.966-18.132 | 0.002 |
Missing | 4 | 4 | Â | Â | Â | Â | Â | Â |
FGF2 & VEGFR-3 | Â | Â | Â | Â | Â | Â | Â | 0.050* |
Low | 51 | 47 | NR | 70 | 0.042 | 1.000 | Â | Â |
Intermediate | 35 | 32 | 120 | 56 | Â | 1.999 | 0.978-4.087 | 0.058 |
High | 16 | 15 | 45 | 46 | Â | 2.584 | 1.106-6.038 | 0.028 |
Missing | 6 | 6 | Â | Â | Â | Â | Â | Â |
FGFR-1 & PDGF-B | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 26 | 24 | NR | 75 | 0.061 | Â | Â | Â |
Intermediate | 56 | 52 | 120 | 55 | Â | Â | Â | Â |
High | 23 | 21 | NR | 58 | Â | Â | Â | Â |
Missing | 3 | 3 | Â | Â | Â | Â | Â | Â |
FGFR-1 & VEGFR-3 | Â | Â | Â | Â | Â | Â | Â | Â |
Low | 57 | 53 | NR | 66 | 0.344 | Â | Â | Â |
Intermediate | 29 | 27 | 120 | 59 | Â | Â | Â | Â |
High | 18 | 17 | 63 | 52 | Â | Â | Â | Â |
Missing | 4 | 4 | Â | Â | Â | Â | Â | Â |